Kieran O'Brien

Kieran has vast experience in class actions/mass torts, product liability/product recalls, complex insurance claims (public liability, professional liability and property damage), commercial litigation.

Kieran is the International Co-Chair of the DLA Piper Class Actions and Collective Redress Group and heads DLA Piper's Australian Product Liability practice.

Kieran regularly advises on mandates that have global reach, working closely with clients and colleagues in the US, Europe and Asia. He assists clients traverse the complexity of cross-border litigation and regulatory action.

Kieran has a particular focus on the Life Sciences, Manufacturing/Industrial, Food and Beverages, Sports and Insurance sectors, and acts for many leading global companies and sporting codes in those sectors.

For instance, Kieran regularly acts for several global life sciences companies (pharmaceuticals and medical devices) in product liability and commercial litigation matters around Australia, and providing litigation and regulatory advice. Recent examples include class action litigation involving pelvic mesh, the Parkinson's Disease treatment drug (Cabaser), various medications including the smoking cessation medication Champix, and a variety of medical devices including hernia mesh, contraceptives, spinal implants and cardiac, ventilation and surgical equipment

Kieran has been included in Best Lawyers in Australia (a publication of the Australian Financial Review) since 2012 for the practice areas of Insurance, Litigation, Product Liability and Class Action. In 2013, Kieran was recognised as a leading lawyer in the International Who's Who of Insurance & Reinsurance Lawyers.

Kieran also actively participates in DLA Piper's Pro Bono program. He has been a partner champion for the UNICEF Child Rights Project, and has taught Civil Procedure to law students at the University of the South Pacific in Port Vila.  Kieran is also a Board Member of Maddie Riewoldt's Vision, a charity dedicated to funding research and treatment into, and ultimately a cure for, bone marrow failure syndromes.